000			01972 a2200493 4500
005			20250515203033.0
264		0	_c20100408
008			201004s 0 0 eng d
022			_a1873-2968
024	7		_a10.1016/j.bcp.2009.12.023 _2doi
040			_aNLM _beng _cNLM
100	1		_aSabisz, Michal
245	0	0	_aIncreased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints. _h[electronic resource]
260			_bBiochemical pharmacology _cMay 2010
300			_a1387-97 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAcridines _xpharmacology
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aBlotting, Western
650	0	4	_aCell Cycle _xdrug effects
650	0	4	_aCell Death _xdrug effects
650	0	4	_aCyclin B1 _xphysiology
650	0	4	_aDNA Damage _xdrug effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDown-Regulation _xdrug effects
650	0	4	_aFlow Cytometry
650	0	4	_aGene Expression Regulation _xdrug effects
650	0	4	_aHeLa Cells _xdrug effects
650	0	4	_aHumans
650	0	4	_aMitosis _xdrug effects
650	0	4	_aPoly (ADP-Ribose) Polymerase-1
650	0	4	_aPoly(ADP-ribose) Polymerase Inhibitors
650	0	4	_aPoly(ADP-ribose) Polymerases _xmetabolism
650	0	4	_aPolyploidy
650	0	4	_aProteasome Endopeptidase Complex _xdrug effects
650	0	4	_aQuinazolines _xpharmacology
650	0	4	_aTopoisomerase II Inhibitors
650	0	4	_aTriazoles _xpharmacology
650	0	4	_aTumor Suppressor Protein p53 _xdrug effects
700	1		_aWesierska-Gadek, Józefa
700	1		_aSkladanowski, Andrzej
773	0		_tBiochemical pharmacology _gvol. 79 _gno. 10 _gp. 1387-97
856	4	0	_uhttps://doi.org/10.1016/j.bcp.2009.12.023 _zAvailable from publisher's website
999			_c19446093 _d19446093